Aquila Diagnostic Systems Inc. is a privately held Canadian company commercializing its innovative Accutas solution for a point-of-care molecular (DNA/RNA) diagnostic testing system. The patented Accutas solution provides low cost, laboratory quality diagnostics at the point-of-care, eliminating cost and inconvenience of waiting days or weeks for laboratory results to be returned and the subsequent follow-up visit or treatment. Aquila is preparing to enter large markets for veterinary and tropical fever diagnostics.

Latest News

posted on July 28, 2015 Aquila joins International Collaboration for the Malaria Vaccine Initiative
July 28, 2015 — Edmonton, Alberta — Aquila Diagnostics Inc. today announced its participation in a project with the PATH Malaria Vaccine Initiative to improve testing for malaria infectiousness.

-
-

posted on June 16, 2015 Aquila to present at the Ag Innovation Showcase in St. Louis, September 14-15
June 16, 2015 – Aquila has been selected by the Canadian Trade Commissioner Service to attend the Ag Innovation Showcase in St. Louis.

-
-

posted on June 15, 2015 Aquila presents at 2015 Agri Investment Forum in Toronto
June 5, 2015 – Toronto, ON, Canada – Aquila CEO Brent James presented the Aquila investment opportunity to investors at the annual Agri Investment Forum.

-
-

posted on March 31, 2015 Second Aquila Patent Issued by USPTO
March 31, 2015 – Aquila Diagnostic Systems Inc. received notice today that the United States Patent and Trademark Office (USPTO) has issued a Patent, “Solid Gel Amplification Method and Apparatus for Genotyping and Pathogen Detection" (Inventors: Alexey Atrazhev, and Jason Acker). This patent is under license to Aquila from the University of Alberta.

-
-

posted on March 24, 2015 First Aquila Patent Issued by USPTO
March 24, 2014 – Aquila Diagnostic Systems Inc. received notice today that the United States Patent and Trademark Office (USPTO) has allowed its Patent Application: "Setting of Multiple Priming Oligonucleotides for Solid Gel Amplification in Hydrogels" (Inventor: Alexey Atrazhev). This patent is under license from the University of Alberta and is the first of a number of patent applications pending for Aquila.

-
-

posted on July 08, 2014 Accutas™ Lab-On-A-Chip Malaria Detection Kit Featured on ABC News
July 8, 2014  - Australia -  Aquila's Accutas™ Lab-On-A-Chip malaria detection kit and Dr. Stephanie Yanow are featured on ABC News.

-
-

posted on June 28, 2014 Aquila Receives Federal WINN Funding
June 27, 2014 - Calgary, AB, Canada - Aquila receives new Federal Government funding under the Western Innovation (WINN) Initiative at an announcement today.

-
-

posted on June 24, 2014 Research showing the effectiveness of Aquila's Accutas™ Lab-On-A-Chip published in Malaria Journal
Research into Aquila's Accutas™ Lab-On-A-Chip system published in the May 2014 issue of Malaria Journal shows the technology's effectiveness at diagnosing malaria. Using patient samples from Uganda, the diagnostic exceeded the standards for microscopy by ten- to fifty-fold, with sensitivity (97.4%) and specificity (93.8%) compared to conventional real-time PCR.

-
-

posted on March 24, 2014 Aquila's Accutas™ Lab-On-A-Chip Featured in Apple Magazine
March 24, 2014 - Edmonton, AB, Canada - The Accutas™ system is recognized among groundbreaking healthcare innovations in Alberta Health Service's Apple magazine.

-
-

posted on March 13, 2014 Aquila Diagnostic Systems Unveils New Accutas™ Lab-On-A-Chip March 13, 2014 – Edmonton, AB, Canada – With a favourable assessment from the Geneva-based Foundation for Innovative New Diagnostics (FIND), Edmonton's Aquila Diagnostic Systems has achieved an important milestone in the development of their point-of-care Accutas™ Lab-On-A-Chip malaria detection kit. 

-
-

Testimonials

“This new technology... opens up the possibility of using a simple and highly sensitive molecular test at the point-of-care for the diagnosis of malaria and other blood-borne infections.”
Chief Scientific Officer Mark Perkins, Foundation for Innovative New Diagnostics (FIND), Geneva, in a favourable assessment showing Aquila’s Accutas™ diagnostic system achieved results superior to current malaria testing systems.
 

Supporters

Alberta Innovates
Broadport Canada Inc
nanobridge small
Western Economic Diversification Canada 120w

9207 117 Street, Edmonton, Alberta, Canada   T6G 1S3

   Subscribe to our newsletter